UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K/A
 

CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 18, 2021
 
 
CYCLERION THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 
 
Massachusetts
001-38787
83-1895370
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)

245 First Street, 18th Floor
Cambridge, Massachusetts 02142

(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (857) 327-8778

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  Trading Symbol(s)   Name of each exchange on which registered
Common Stock, no par value
 
CYCN
 
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.
Other Events

On March 18, 2021,  Cyclerion Therapeutics, Inc. issued a press release announcing the resignation of its Chief Medical Officer, Christopher Wright, M.D., Ph.D., and his joining its Clinical Advisory Board. A corrected copy of the press release, indicating March 26, 2021 as the date until which transitional support will be provided, is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01
Financial Statements and Exhibits.
 
(d)
 
Exhibit No.
Description
   
Press Release dated March 18, 2021

2
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Cyclerion Therapeutics, Inc.
     
Dated: March 18, 2021
By:
/s/ Anjeza Gjino
   
Name:
Anjeza Gjino
   
Title:
Chief Financial Officer


3
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cyclerion Therapeutics Charts.
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cyclerion Therapeutics Charts.